OPEN Advocacy and Coverage Issues
ACCC Advocacy
Coverage and Other Payment Issues. Medicare's current coverage rules effectively provide beneficiary access to innovative therapies, used in conformity with evolving standards of care. The Medicare statute requires carriers to cover off-label uses of cancer therapies when such uses are supported by citations in certain compendia or by clinical evidence in peer-reviewed literature.
Off-Label Coverage Issues
Erythropoiesis Stimulating Agents (ESAs) Issues
- FDA Approves Changes to ESA Labeling
- ACCC Request to Reconsider ESA NCD
- Proposed Decision Memo for Erythropoiesis Stimulating Agents (ESAs) for non-renal disease indications
- ACCC's Comments on CMS's NCA Tracking Sheet for Erythropoiesis Stimulating Agents (ESAs) for Non-Renal Disease Indications
- Frequently Asked Questions On Use of Erythropoiesis Stimulating Agents (ESAs) in Cancer and Related Neoplastic Conditions
- ACCC Hospital Survey Impact of Proposed NCD on ESAs for Hospitals